LSD analogs (lysergamides: 1P-LSD, 1cP-LSD, 1V-LSD, AL-LAD)

psilodex.org/m/lysergamides · data v2026.10.02

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Other psychedelic; Also: mechanism only.
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: lysergamides · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

XP · Th

1P-LSD and related 1-acyl analogs convert to LSD in the body (human data for 1P-LSD), so LSD's cross-tolerance with psilocybin, shown in human studies, is expected to apply. AL-LAD and similar analogs act directly. Blotter contents are unverified.

Human data with psilocybin: None with psilocybin; human data with another psychedelic

Evidence types on this record

XPHuman data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

None listed

No pharmacology properties of concern are listed for this record.

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Grumann C, Henkel K, Brandt SD, et al. Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration. Drug Test Anal 2020;12(8):1144–1153. — oral 1P-LSD yielded only LSD in serum; ~100% bioavailability as LSD (n=2 humans)
Halberstadt AL, Chatha M, Klein AK, et al. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). Neuropharmacology 2020;172:107856. — ALD-52, 1P-LSD, 1B-LSD rapidly deacylated to LSD in vivo
Berquist MD, Gannon BM, Honeywell KM, et al. Interoceptive effects of N-substituted lysergamides in rats: role of agonist affinity at 5-hydroxytryptamine receptors and in vivo metabolism to lysergic acid diethylamide. J Pharmacol Exp Ther 2026:104988. — 1A-, 1P-, 1B-, 1CP-LSD converted to LSD in rats
Brandt SD, Kavanagh PV, Westphal F, et al. Return of the lysergamides. Part III: analytical characterization of N-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). Drug Test Anal 2017;9(10):1641–1649. — 1P-LSD, AL-LAD, LSZ sold as blotters/powders on the NPS market
Isbell H, Wolbach AB, Wikler A, Miner EJ. Cross tolerance between LSD and psilocybin. Psychopharmacologia 1961;2:147–159. — LSD–psilocybin cross-tolerance in humans

Record history

v2026.10.02First published.
2026-10-02Last reviewed against its sources.

Report an error in this record →